MFN Hub: Most Favored Nation Drug Pricing
Your central resource for understanding Most Favored Nation (MFN) drug pricing and international reference pricing (IRP) in the United States. Explore all four US MFN pathways: GENEROUS (Medicaid), GLOBE (Medicare Part B), GUARD (Medicare Part D), and voluntary manufacturer MFN agreements.
MFN Expert Analysis and Policy Insights
Deep-dive analysis of MFN drug pricing policies, strategic implications, and implementation details from the Symaptics team.
Introducing SyMAP 2.0: From Pricing Simulation to Pricing Strategy
Reference pricing, US MFN and revenue now run as one simulation, the voluntary agreements get a deal designer with a Section 232 tariff overlay, and Optimizer Studio searches the strategy space.
Read Article →The Art of the MFN Deal: the CEA’s $600B Report
The CEA has put a ~$600 billion price tag on MFN. The part that matters for manufacturers: the voluntary deals now reach the commercial market, and signing means weighing tariff relief against years of exposure.
Read Article →Introducing SyMAP MFN: GENEROUS, GLOBE and GUARD in One Model
Three CMS models, three sets of mechanics, one portfolio. Why their outputs cannot be added together, and what it takes to get a single combined MFN exposure figure with each model’s share of it.
Read Article →MFN and the Shift of Risk for Ex-US Markets
Although MFN policies are designed for the US, they shift pricing and policy risk onto ex-US health systems. How ex-US payers adapt will shape future access and investment.
Read Article →Redefining Ex-US Success in an MFN World
Ex-US success is no longer defined by rapid launch and broad footprint, but by deliberate, portfolio-level decisions that protect global value.
Read Article →The End of Two Silos
Why pharmaceutical pricing is now a single global challenge. MFN creates unprecedented integration between U.S. and ex-US pricing strategies.
Read Article →GLOBE & GUARD: MFN Comes to Medicare
Comprehensive analysis of the two Medicare MFN models: 19-country reference baskets, benchmark methodologies, and key implementation differences.
Read Article →The Fine Print: Hidden Details in GLOBE & GUARD
Three overlooked provisions that could reshape your MFN strategy: PPP adjustments, benchmark lock-in, and Method II pricing dynamics.
Read Article →GENEROUS: Medicaid’s MFN Test
What CMS’s voluntary Medicaid model means for manufacturers: 8-country basket, GNUP calculations, and supplemental rebate obligations.
Read Article →MFN Demands a Truly Global Pricing Strategy
For decades, pharmaceutical pricing operated in two separate worlds. U.S. teams focused on net pricing, rebates, and channel management. Ex-US teams managed list prices, IRP networks, and launch sequencing. That era is ending.
With MFN policies now active, international prices directly shape U.S. Medicare and Medicaid outcomes. Pricing strategy can no longer be siloed: decisions in one market have direct consequences in others.
These MFN policies represent the U.S. adoption of international reference pricing (IRP), a methodology widely used in Europe and other markets. IRP benchmarks domestic prices against a basket of reference countries, and with MFN, the U.S. now joins the global IRP network that pharmaceutical companies must navigate when setting prices.
MFN Programmes & Agreements
Four MFN initiatives now shape pharmaceutical pricing in the United States: three government programmes and voluntary manufacturer agreements, each using international reference pricing mechanisms.
GENEROUS
GENErating cost Reductions fOr U.S. Medicaid
Voluntary CMS model using PPP-adjusted net prices from G-7 countries (ex-US) plus Denmark and Switzerland to set Medicaid supplemental rebates.
GLOBE
Global Benchmark for Efficient Drug Pricing
Medicare Part B model using international benchmarks from 19 OECD countries meeting GDP criteria. Affects physician-administered drugs.
GUARD
Guarding U.S. Medicare Against Rising Drug Costs
Medicare Part D model embedding international benchmarks in inflation rebate calculations. Creates pricing uncertainty for retail pharmacy drugs.
MFN Agreements
Manufacturer MFN Pricing Commitments
Voluntary bilateral agreements to offer MFN-level pricing. Existing drugs reach Medicaid and direct-to-consumer buyers via TrumpRx.gov; future launches are priced at MFN across all U.S. channels, including commercial.
MFN Pricing Tools
Select tools from the ribbon below to take an interactive dive into government MFN programs.
MFN Program Timeline Viewer
View Full WindowInteractive animated timeline showing key dates, milestones, and deadlines for GENEROUS, GLOBE, and GUARD programs from 2025-2033.
Desktop Only
The interactive timeline is best experienced on a desktop or laptop. Please visit on a larger screen to explore the full timeline.
GENEROUS Supplemental Rebate Calculator
Calculate the supplemental rebate required to achieve the Guaranteed Net Unit Price (GNUP) under the GENEROUS model.
Supplemental Rebate = WAC − (GNUP + URA)The supplemental rebate bridges the gap between standard Medicaid pricing and MFN-level pricing.
Interactive: Launch Sequencing Impact on GENEROUS
Drag country bars to adjust launch dates. Edit net prices to model different scenarios. See how timing and pricing affect the PPP-adjusted GENEROUS reference price across model years.
GENEROUS Reference Price by Model Year
PPP-adjusted reference price = 2nd lowest (Net Price × PPP Adjuster) from countries launched before capture period ends
MFN Reference Country Map
Explore reference countries used in MFN pricing models. Toggle filters to see which countries are included in each scheme.
Loading reference country map…
MFN Scheme Comparison
How the government MFN schemes and manufacturer agreements compare across key dimensions.
| GENEROUS | GLOBE | GUARD | MFN Agreements | |
|---|---|---|---|---|
| Target Programme | MedicaidState-administered health coverage for low-income individuals. GENEROUS targets supplemental rebate agreements with participating states. | Medicare Part BCovers physician-administered drugs (infusions, injections in clinical settings). Reimbursed via Average Sales Price (ASP) methodology. | Medicare Part DCovers self-administered drugs dispensed at retail pharmacies. Subject to IRA inflation rebates. | Medicaid, DTC & commercialFor existing drugs, agreements cover Medicaid and direct-to-consumer access via TrumpRx.gov. For future launches, prospective MFN applies across all U.S. markets, including commercial/private insurance. |
| Drug Coverage | Single source & innovator drugsDrugs without generic competition and brand-name products. Excludes generic drugs and biosimilars. | Physician-administered drugsSingle source drugs and sole source biologicals with Medicare Part B FFS spending >$100M over 12 months. Must be subject to Part B inflation rebates. Excludes IRA Maximum Fair Price drugs and 340B units. Limited to selected USP drug categories. | Retail pharmacy drugsSole-source drugs and biologicals with annual Medicare spending above $69M (2027, adjusted by CPI-U annually). Must be subject to Part D inflation rebates. Excludes IRA Maximum Fair Price drugs, 340B units, generics, and biosimilars. | Signatory company productsCovers products from the 17 signatory manufacturers. Signatories include Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, EMD Serono, Genentech, Gilead, GSK, Merck, Novartis, Novo Nordisk, Pfizer, and Sanofi. |
| Reference Countries | 8 (G-7 ex-US + DK, CH)G-7 countries excluding US: Canada, France, Germany, Italy, Japan, UK. Plus Denmark (DK) and Switzerland (CH). Fixed 8-country set. | 19 (OECD, GDP criteria)OECD members meeting: (1) per capita GDP (PPP) ≥60% of US and (2) aggregate GDP (PPP) ≥$400B. Countries: Australia, Austria, Belgium, Canada, Czech Republic, Denmark, France, Germany, Ireland, Israel, Italy, Japan, Netherlands, Norway, South Korea, Spain, Sweden, Switzerland, UK. | 19 (OECD, GDP criteria)OECD members meeting: (1) per capita GDP (PPP) ≥60% of US and (2) aggregate GDP (PPP) ≥$400B. Countries: Australia, Austria, Belgium, Canada, Czech Republic, Denmark, France, Germany, Ireland, Israel, Italy, Japan, Netherlands, Norway, South Korea, Spain, Sweden, Switzerland, UK. | G-7 ex-US + DK, CHThe voluntary framework references the same basket as GENEROUS: the G-7 nations excluding the U.S., plus Denmark and Switzerland, the domiciles of the top 10 pharma companies by market cap. MFN is the 2nd lowest PPP-adjusted net price. |
| Price Source | Net prices (after rebates)Confidential prices after all discounts and rebates. Typically 30-50% below published list prices. | List or net (manufacturer choice)Two methods: Method I uses public ex-manufacturer/list prices from CMS data sources. Method II allows manufacturers to voluntarily submit verified volume-weighted net prices. | List or net (manufacturer choice)Two methods: Method I uses public ex-manufacturer/list prices. Method II allows manufacturers to voluntarily submit verified volume-weighted net prices. | International net pricesUses confidential net prices (after rebates and discounts) from international markets. Typically 30-50% below U.S. list prices, reflecting true transaction prices abroad. |
| Benchmark Method | 2nd lowest PPP-adjustedFrom the 8 reference countries, prices are adjusted by GDP purchasing power parity (PPP), then the 2nd lowest price sets the benchmark. | Higher of Method I or IICMS uses the HIGHER of: Method I (lowest country list price × PPP adjuster × 1.02) or Method II (volume-weighted avg net price × PPP adjuster × 1.05). Method I is fixed once set; Method II can be updated periodically. | Higher of Method I or IICMS uses the HIGHER of: Method I (lowest country list price × PPP adjuster × 1.02) or Method II (volume-weighted avg net price × PPP adjuster × 1.05). Method I is fixed once set; Method II can be updated periodically. | 2nd lowest PPP-adjustedThe reference is the 2nd lowest PPP-adjusted net price across the basket. Using the 2nd lowest price limits distortion from a single outlier market and creates clearer targets for trade negotiations. |
| Participation | VoluntaryManufacturers and states opt in. No penalty for non-participation. National framework with state enrollment. | Mandatory (in test regions)Mandatory for manufacturers of qualifying Part B drugs with >$100M annual Medicare spend. Tested in randomised geographic areas (ZIP Code Tabulation Areas). | Mandatory (in test regions)Mandatory for manufacturers of qualifying Part D drugs meeting spend thresholds. Tested in randomised geographic areas (ZIP Code Tabulation Areas). | VoluntaryManufacturers voluntarily sign bilateral agreements with the administration. 17 major pharmaceutical companies have signed as of 2026. No regulatory penalty for non-participation, though holding out carries exposure to tariffs and the mandatory CMS models. |
| Implementation | Supplemental rebatesStates invoice manufacturers for additional rebates beyond the standard Medicaid Drug Rebate Program (MDRP) amounts. | ASP adjustmentInternational benchmark compared within quarterly Part B inflation rebate framework. Calculates incremental rebate above inflation baseline based on difference between ASP and benchmark price per billing unit. | Inflation rebate modifierInternational benchmark applied against performance-year Medicare net price (WAC minus rebates/discounts). GUARD liability applies only where it exceeds the Part D inflation rebate baseline. | Direct pricing commitmentManufacturers commit to offering MFN-level pricing directly. Existing products are available at international net prices via TrumpRx.gov and Medicaid; all future launches must be priced at MFN across every U.S. channel, including commercial. |
| Start Date | January 1, 2026 | October 1, 2026 | January 1, 2027 | January 2026 |
| Duration | 5 years (2026-2030)Model Year 1 (2026) through Model Year 5 (2030). Voluntary enrollment with annual participation commitments. | 5 performance yearsPerformance period: Oct 1, 2026 to Sep 30, 2031 (5 years). Plus extended invoicing/collection/reconciliation windows through 2033. Total ~7-year test period. | 5 performance yearsPerformance period: Jan 1, 2027 to Dec 31, 2031 (5 years). Plus extended invoicing/collection/reconciliation windows through 2033. Total ~7-year test period. | OngoingNo fixed end date. Agreements remain in effect as long as manufacturers maintain participation. Terms may be renegotiated or extended based on policy changes. |
SyMAP MFN
Your comprehensive platform for Most Favored Nation drug pricing analysis. Model GENEROUS, GLOBE, GUARD, and voluntary manufacturer agreement scenarios New in 2.0 across your portfolio, with revenue forecasts under voluntary, CMS, and baseline policy paths, AI-powered insights, and decision support.
Frequently Asked Questions About MFN Drug Pricing
Most Favored Nation (MFN) drug pricing is a policy approach that ties U.S. drug prices to lower prices in other countries. Under MFN models, Medicare and Medicaid use international reference prices from a basket of countries to set or cap drug reimbursement rates, aiming to reduce U.S. drug costs.
The three CMS schemes are: (1) GENEROUS – a voluntary Medicaid model using 8 reference countries, active since January 2026; (2) GLOBE – a Medicare Part B model using 19 countries, starting October 2026; and (3) GUARD – a Medicare Part D model also using 19 countries, starting January 2027. In addition, manufacturers are signing voluntary MFN agreements directly with the US government, a fourth MFN pathway alongside the three CMS schemes, covered in the MFN Agreements section above.
GENEROUS uses 8 countries: Canada, France, Germany, Italy, Japan, UK, Denmark, and Switzerland. GLOBE and GUARD use 19 OECD countries meeting GDP criteria: Australia, Austria, Belgium, Canada, Czech Republic, Denmark, France, Germany, Ireland, Israel, Italy, Japan, Netherlands, Norway, South Korea, Spain, Sweden, Switzerland, and the UK.
MFN creates direct linkage between U.S. and international pricing. Changes to list or net prices in reference countries now affect U.S. Medicare and Medicaid reimbursement. This requires pharmaceutical companies to adopt integrated global pricing strategies rather than managing U.S. and ex-US pricing separately.
International reference pricing (IRP) is a pricing methodology where a country sets or caps drug prices based on prices in other countries. MFN policies are the U.S. implementation of IRP: GENEROUS, GLOBE, and GUARD all use reference baskets of other nations’ prices to determine U.S. Medicare and Medicaid reimbursement rates. You can simulate IRP cascades (and their MFN consequences) in SyMAP IRP.